Compare
Corbus Pharmaceuticals Holdings, Inc. vs Climb Bio, Inc. vs Gyre Therapeutics, Inc. vs Gossamer Bio, Inc.
| Latest fiscal year | Corbus Pharmaceuticals Holdings, Inc. CRBP | Climb Bio, Inc. CLYM | Gyre Therapeutics, Inc. GYRE | Gossamer Bio, Inc. GOSS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $116.59M | $48.47M |
| Revenue growth (YoY) | n/a | n/a | +10.2% | -57.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | 9.9% | -352.2% |
| Net margin | n/a | n/a | 8.5% | -351.5% |
| Net income | -$78.54M | -$59.85M | $9.88M | -$170.37M |
| EPS (Diluted) | -$5.90 | -$0.88 | $0.02 | -$0.75 |
| Operating cash flow | -$64.49M | -$54.36M | $1.01M | -$171.27M |
| Free cash flow | -$64.50M | -$54.54M | -$180.0K | -$171.34M |
| Cash & equivalents | $28.49M | $35.69M | $37.07M | $37.73M |
| Total assets | $168.19M | $167.74M | $166.13M | $172.25M |
| Total liabilities | $20.69M | $7.27M | $23.85M | $295.01M |
| Shareholders' equity | $147.50M | $160.47M | $106.03M | -$122.76M |
| Return on year-end equity | -53.2% | -37.3% | 9.3% | n/a |
| Shares outstanding | 17.61M | 47.77M | 91.31M | 233.68M |
Revenue, most recent five fiscal years
| Fiscal year | Corbus Pharmaceuticals Holdings, Inc. | Climb Bio, Inc. | Gyre Therapeutics, Inc. | Gossamer Bio, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2022-12-31 | n/a | $116.59M Ended 2025-12-31 | $48.47M Ended 2025-12-31 |
| 1 year earlier | $881.7K Ended 2021-12-31 | n/a | $105.76M Ended 2024-12-31 | $114.70M Ended 2024-12-31 |
| 2 years earlier | $3.94M Ended 2020-12-31 | n/a | $113.45M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $36.14M Ended 2019-12-31 | n/a | $102.29M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $4.82M Ended 2018-12-31 | n/a | $7.34M Ended 2021-12-31 | n/a |